Why New Antibiotics Struggle to Pay Their Way
Biotech·October 26, 2026
The central problem with antibiotics is easy to state and hard to solve. A new drug has to beat bacteria that already shrug off existing treatments, yet doctors need to save it for the most severe infections. Use it too widely and bacteria evolve resistance to it as well, and the drug stops working for everyone. That restraint is good for public health, but it leaves the company that made the drug with very few prescriptions to sell.
The third and final episode of Discovery's three-part superbugs series, reported by Roland Pease, focuses on that business problem. It asks how a drug kept in reserve can ever generate enough revenue to repay the cost of developing it. According to the episode's summary, several leading antibiotic companies have run into serious financial trouble over roughly the past eight years, and the mismatch between medical need and commercial reward is a major reason why.
The economics are unforgiving. Bringing a new antibiotic through clinical trials is expensive and slow. Once approved, the drug may be prescribed to a relatively small group of patients, and stewardship rules deliberately limit how often it is used. Most drugs for chronic conditions are taken daily for years, which is the kind of steady sales curve investors like. Antibiotics rarely offer that. A company can spend heavily, win approval, and then find that sales never cover the bill.
The episode's central question is whether the market can be redesigned so that antibiotic development pays. Policymakers have discussed several options, including guaranteed payments or subscription contracts, where a government pays a fixed fee for access to a drug whatever the volume of prescriptions. The United Kingdom has tested a version of this approach. Other proposals would reward developers for the public health value of a new drug rather than the number of doses sold.
For patients, the stakes are immediate. Resistant infections already contribute to deaths, and without new drugs, common procedures such as surgery and cancer treatment carry a greater risk of infection. The series makes clear that the shortage of new antibiotics is not only a scientific challenge. It is also a question of how the market, and the state, chooses to reward the work of finding them.
Reporting based on an external source.